CT
CSCI

Cambridge Trust’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Cambridge Trust’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1
Closed -$5K – 239
2015
Q1 		$5K Hold
1
– – ﹤0.01% 229
2014
Q4 		$6K Buy
+1
New +$8.4K ﹤0.01% 222

Other funds holding CSCI

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
NCCM
Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Azzad Asset Management Falls Church, Virginia $1.13B AUM 38.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Cambridge Trust's CSCI Position: Q2 2015 in Review

Cambridge Trust sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q2 2015, closing a stake of 1 share — an estimated $5K sold.

Cambridge Trust first reported a position in CSCI in Q4 2014 and held it in 2 quarters. The position peaked at $6K in Q4 2014. 10 funds tracked by Wall St. Rank hold CSCI as of Q2 2015.

  • Cambridge Trust reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Cambridge Trust sold 1 COSCIENS Biopharma Inc. Common Stock share in Q2 2015, an estimated $5K.
  • Cambridge Trust first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2014 and held it in 2 quarters.
  • Cambridge Trust's COSCIENS Biopharma Inc. Common Stock position peaked at $6K in Q4 2014.
  • 10 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q2 2015.

Based on Cambridge Trust's 13F filing for Q2 2015, filed 5 Aug 2015.